For the quarter ending 2026-03-31, NVCT had -$6,504K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -6,050 | -7,314 | -7,462 | -11,666 |
| Cost of share-based payments | 1,850 | 1,476 | 1,457 | 3,099 |
| Increase in other current assets | 193 | -70 | -69 | 140 |
| (decrease)/increase in accounts payable | -1,579 | -165 | 1,462 | 2,479 |
| (decrease)/increase in accrued liabilities | -79 | 50 | 63 | -838 |
| Increase in employee compensation and benefits | -460 | 1,909 | -83 | -475 |
| Issuance costs-Public Offering | - | 0 | 0 | 1,552 |
| Net cash used in operating activities | -6,511 | -3,974 | -4,494 | -7,541 |
| Issuance costs-At Market Offering | - | 82 | 407 | 59 |
| Proceeds from issuance of common shares-Public Offering | - | 0 | 0 | 15,525 |
| Net cash provided by (used in) investing activities | 0 | - | - | 0 |
| Proceeds from issuance of common shares | 7 | 248 | 13,550 | 1,887 |
| Net cash provided by financing activities | 7 | 166 | 13,143 | 15,801 |
| (decrease)/increase in cash and cash equivalents | -6,504 | -3,808 | 8,649 | 8,260 |
| Cash and cash equivalents at beginning of period | 31,634 | 35,442 | 18,533 | - |
| Cash and cash equivalents at end of period | 25,130 | 31,634 | 35,442 | - |
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)